182 related articles for article (PubMed ID: 29956623)
1. Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Platelet-derived Growth Factor Receptor (PDGFR) Kinase Inhibitors.
Qian Y; Yu L; Zhang XH; Yuan ZQ; Zhao P; Sun LN; Wang YQ
Curr Drug Metab; 2018; 19(14):1168-1181. PubMed ID: 29956623
[TBL] [Abstract][Full Text] [Related]
2. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Mar; 129():65-83. PubMed ID: 29408302
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
4. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.
Dai Y
Expert Opin Ther Pat; 2010 Jul; 20(7):885-97. PubMed ID: 20509775
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.
Polillo M; Galimberti S; Baratè C; Petrini M; Danesi R; Di Paolo A
Int J Mol Sci; 2015 Sep; 16(9):22811-29. PubMed ID: 26402671
[TBL] [Abstract][Full Text] [Related]
6. Risk of Thrombocytopenia With Platelet-Derived Growth Factor Receptor Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized, Controlled Trials.
Liu Y; Sun W; Li J
J Clin Pharmacol; 2021 Nov; 61(11):1397-1405. PubMed ID: 34241895
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
[TBL] [Abstract][Full Text] [Related]
8. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
Chen YC; Chen JH; Hsieh FI
J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
[TBL] [Abstract][Full Text] [Related]
9. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.
Demetri GD
Semin Oncol; 2011 Apr; 38 Suppl 1():S10-9. PubMed ID: 21419931
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.
Gay C; Toulet D; Le Corre P
Hematol Oncol; 2017 Sep; 35(3):259-280. PubMed ID: 27925256
[TBL] [Abstract][Full Text] [Related]
11. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells.
Li M; Ping G; Plathow C; Trinh T; Lipson KE; Hauser K; Krempien R; Debus J; Abdollahi A; Huber PE
BMC Cancer; 2006 Mar; 6():79. PubMed ID: 16556328
[TBL] [Abstract][Full Text] [Related]
12. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Giles FJ; O'Dwyer M; Swords R
Leukemia; 2009 Oct; 23(10):1698-707. PubMed ID: 19474800
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis.
Makita N; Iiri T
Thyroid; 2013 Feb; 23(2):151-9. PubMed ID: 23398161
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
16. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
17. [Tyrosine kinase inhibitors].
Robert J
Bull Cancer; 2011 Nov; 98(11):1321-34. PubMed ID: 22023787
[TBL] [Abstract][Full Text] [Related]
18. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
20. Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology.
Fujita KI; Ishida H; Kubota Y; Sasaki Y
Curr Drug Metab; 2017; 18(3):186-198. PubMed ID: 28059038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
